With over 18,000 members representing oncology professionals from over 150 countries, the European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology. ESMO’s educational resources are built upon an integrated, multidisciplinary approach to cancer care.
The ESMO 20th World Congress on Gastrointestinal Cancer brings together over 3500 leading gastroenterology, oncology, pathology, and hepatology experts, clinicians, and surgeons, as well as clinical researchers from across the globe to share pioneering research, approaches, and best practices in treating patients with cancers of the gastrointestinal tract.
Journal of Clinical Pathways was onsite at the conference to provide coverage of the presentations.
Patients with metastatic colorectal cancer (mCRC) treated in the real-world setting experienced comparable survival benefits and safety outcomes compared with clinical trials, despite more than half of patients starting on a dose lower than the approved dose.
Adjuvant Chemotherapy Regimen Represents New Standard of Care for Resected Pancreatic Cancer
Adjuvant chemotherapy with a modified FOLFIRINOX regimen is superior to gemcitabine after pancreatic cancer resection and should now be considered a new standard of care.
